We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Glaxo Pays $175 Million To Settle Antitrust Suit Over Relafen Patent

Law360 (February 7, 2004, 12:00 AM EST) -- GlaxoSmithKline has agreed to pay $175 million to settle a lawsuit alleging that the company had violated U.S. antitrust law by blocking generic versions of its Relafen arthritis medicine.

The U.K. drug maker, the largest in Europe, said the settlement is being submitted for review Friday to the U.S. District Court for the District of Massachusetts, where the case has been pending since 2001.

Consumers, health plans and pharmacies have sued drug companies on allegations that they misused patents to block low-cost alternatives to their medicines....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.